{"name":"Orexigen Therapeutics, Inc","slug":"orexigen-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":33709000,"revenueGrowth":37.8,"grossMargin":0,"rdSpend":38023000,"netIncome":-24524000,"cash":92494000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NB","genericName":"NB","slug":"nb","indication":"Chronic weight management in obese or overweight adults with weight-related comorbidities","status":"marketed"}]}],"pipeline":[{"name":"NB","genericName":"NB","slug":"nb","phase":"marketed","mechanism":"NB (naltrexone/bupropion) is a combination drug that reduces appetite and increases energy expenditure through opioid antagonism and norepinephrine/dopamine reuptake inhibition.","indications":["Chronic weight management in obese or overweight adults with weight-related comorbidities"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBZQ2Y2UnZJLWtZT041Z0RTVXdPVTcxaXM3QnBQX3R0dXFQS3VwSldVUGxxckVPU0VpZHFqMlpaOS10aHB4VjVYUzM1TDB4eWdhN0Mwbm5tWW1sbEExM0ZIQ0ZPaWc?oc=5","date":"2025-11-26","type":"pipeline","source":"Market.us","summary":"Prescription appetite suppressants - Market.us","headline":"Prescription appetite suppressants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOckxuelV4cmxyRkI0NTN4T2VaLV82RHo0cHd5WVFKWlQ5NFVTMXZUZUNmdzI0Ylk0allXd3pFWEh1eFRZQm4wTkZhR0NlbVJYLXRfX196U2hXZ3huUlpVTGswdkZuX1BrbWRDdV8wWGdZVFpMNXB4U1VCbE5FY3Ewd210VF9Wd2FKRkw3OEJXTXB0NGpDRTVOOHJha2duYnRucmdDSVF6dFowZw?oc=5","date":"2025-09-22","type":"pipeline","source":"Pharmaceutical Online","summary":"Pfizer Strengthens Obesity Foothold With Metsera Acquisition - Pharmaceutical Online","headline":"Pfizer Strengthens Obesity Foothold With Metsera Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNRVg1dmpfNElBVzhlUHpfOUdNWmJPQktvZkRaamNJMjBsT0xwdU1LM1QxcV90OUJDNGpaS19Eb0p6aHhDRHJ3cnh3elMxNVNzNGJZOEhFdzJ6SG14Z2lVZXdBZDJpTzZrMzBqX3pWbEEwVVQxS0hxUTdPYXFYci1Ld185ek9SQ2E1bUFNQVlYenR0c1MwUDdQTmJoak5IdVMzTjhvZ2lqRFE0RjVzaElUME9TTVc?oc=5","date":"2024-03-19","type":"pipeline","source":"Fierce Biotech","summary":"The obesity pipeline was 'late breaking.' Here's what the R&D landscape looks like now - Fierce Biotech","headline":"The obesity pipeline was 'late breaking.' Here's what the R&D landscape looks like now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOVVdna0pZOW85Z2VsY0tURl9UNnRVNGNPdW1MdnktOV9zZElzYnhXdExCcmpQNTd5NEVmOFNWMUh1ZHoxWkh1TlFKU2lVU2pBU05VZEtmZWRJYUhlOTRzSEREQ1J6TnpXU2JFVmNXblBoRmhpb0lrU0JtNi1nM0cwYVo0b1U5dE1oTjRaaDItRHZ3UklUbVVj?oc=5","date":"2023-03-30","type":"pipeline","source":"citybiz","summary":"Zevra Therapeutics Appoints Wendy Dixon, Ph.D., To Board - citybiz","headline":"Zevra Therapeutics Appoints Wendy Dixon, Ph.D., To Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPODAwSzFiaTcwRlpHR2dTNFJXZC1FRl9MV0lia2c3LUY5aVoxa3lnR0FwNUh4ZWFLVU9uOFZKdGJWSFNQM3VRMGtyc0hueEdpdDhBekd5aTE2SXVfMnUwdG9zVTQtM1ZCcER1cmxVU0ZEajhnWHFxWllya243RlhWbUJTUU1jVV96SXc?oc=5","date":"2022-01-12","type":"pipeline","source":"Pharma Voice","summary":"John Crowley — Journey of the Heart - Pharma Voice","headline":"John Crowley — Journey of the Heart","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUzE4RW81U3pmRTBRTExQY3VzTWhhcTRoV0dDYU5POHlYOW9zVjFGUV9ZMXZQdDJvR0lzd09pZTFpYWR1SkN6a0E2MEhYOTZDUVJ0V3RVZ05iRVVCU1lEd1dFQkE3Zm54ZkJndGFtUVh0dlRrX3BpTlJyak1fV29ZVmtxQVFQUDkySC1iQkptZ0psaXFpU1dmV1Q4RkozM211Q2ZublZEMFVWTFhkZDBmRlZMZW9IRmds?oc=5","date":"2021-05-18","type":"pipeline","source":"Jones Day","summary":"First Impressions: Third Circuit Scuttles Triangular Setoff in Bankruptcy - Jones Day","headline":"First Impressions: Third Circuit Scuttles Triangular Setoff in Bankruptcy","sentiment":"neutral"},{"date":"2019-05-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-05-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2019-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2018-12-19","type":"pipeline","source":"GlobeNewswire","summary":"Nalpropion Pharmaceuticals, Inc. Expands Agreement with - GlobeNewswire","headline":"Nalpropion Pharmaceuticals, Inc. Expands Agreement with","sentiment":"neutral"},{"date":"2018-12-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2018-12-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2018-10-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":33709000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":33709000,"period":"2016-12-31"},{"value":24459000,"period":"2015-12-31"},{"value":9974000,"period":"2015-09-30"},{"value":5194000,"period":"2015-06-30"},{"value":4359000,"period":"2015-03-31"},{"value":55521000,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":38023000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-24524000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":92494000,"cashHistory":[],"totalAssets":304589000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}